The initiation of coverage by B. Riley Securities with a Buy rating and a price target that is potentially higher than the current trading price can be seen as a strong positive endorsement for Tango Therapeutics. This could lead to increased investor interest and a potential short-term rise in the stock price, assuming market conditions do not change significantly.